300501.SHE Shanghai Haishun New Pharmaceutical Packaging Co Ltd
- Market cap
- CNY 2.90B
- P/E
- -
- P/B
- 1.92x
- ROE
- -1.3%
- Dividend yield
- 3.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300501.SHE undervalued?
Graham numberThe Graham number of Shanghai Haishun New Pharmaceutical Packaging Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Haishun New Pharmaceutical Packaging Co Ltd fundamental analysis
No fundamental analysis for Shanghai Haishun New Pharmaceutical Packaging Co Ltd yet.
Shanghai Haishun New Pharmaceutical Packaging Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Haishun New Pharmaceutical Packaging Co Ltd
HySum Flexibles Global, Inc. engages in the manufacture, sale, and export of pharmaceutical packaging products in China and internationally. The company offers pharmaceutical packaging products, including cold-form, tropical blister foil, PVC/Aclar sheets, PTP lidding, hipack child-resistant packaging, hipack AL/PE strip packs, hipack complex laminated flexible films, lamination foil and pouch, composite films, hipack AL/PE suppository laminates, PVC, PVDC/PVC pharmaceutical…
Full company profileShanghai Haishun New Pharmaceutical Packaging Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Haishun New Pharmaceutical Packaging Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 301M | 376M | 507M | 621M | 714M | 857M | 1.01B | 1.02B | 1.14B | 1.10B | 1.32B |
| Gross Profit | 116M | 140M | 165M | 193M | 241M | 244M | 268M | 295M | 310M | 221M | 285M |
| Operating Income | 72.9M | 76.0M | 76.9M | 73.9M | 119M | 118M | 123M | 109M | 97.4M | 18.3M | 75.0M |
| EBITDA | 80.6M | 86.9M | 101M | 113M | 163M | 164M | 172M | 196M | 208M | 116M | 32.4M |
| Net Income | 64.6M | 65.8M | 66.2M | 67.0M | 103M | 105M | 102M | 85.4M | 74.6M | -23.3M | -18.6M |
| EPS | 0.44 | 0.43 | 0.44 | 0.43 | 0.67 | 0.64 | 0.53 | 0.44 | 0.39 | -0.13 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 684M | 710M | 942M | 1.23B | 1.41B | 2.26B | 2.31B | 2.99B | 2.89B | 2.91B | 2.88B |
| Total Liabilities | 89.5M | 76.2M | 228M | 472M | 529M | 679M | 626M | 1.06B | 1.06B | 1.19B | 1.34B |
| Shareholders' Equity | 573M | 612M | 645M | 694M | 805M | 1.51B | 1.60B | 1.83B | 1.74B | 1.56B | 1.45B |
| Cash & Short-term Investments | 107M | 120M | 63.9M | 109M | 100M | 663M | 352M | 767M | 479M | 445M | 308M |
| Total Debt | 10.0M | 24.1M | 91.8M | 220M | 302M | 374M | 291M | 700M | 679M | 931M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 33.5M | 55.1M | 27.5M | 95.9M | 77.5M | 140M | 137M | 101M | 161M | 163M | - |
| Capital Expenditure | 57.2M | 45.8M | 67.7M | 83.3M | 139M | 242M | 347M | 299M | 171M | 74.7M | 33.7M |
| Free Cash Flow | -23.8M | 9.31M | -40.2M | 12.6M | -61.2M | -102M | -210M | -198M | -9.68M | 87.8M | 20.4M |
| Ratios | |||||||||||
| ROE | 11.3% | 10.8% | 10.3% | 9.7% | 12.8% | 6.9% | 6.4% | 4.7% | 4.3% | -1.5% | -1.3% |
| ROA | 9.4% | 9.3% | 7.0% | 5.4% | 7.3% | 4.6% | 4.4% | 2.9% | 2.6% | -0.8% | -0.6% |
| Net Profit Margin | 21.4% | 17.5% | 13.0% | 10.8% | 14.4% | 12.2% | 10.1% | 8.4% | 6.5% | -2.1% | -1.4% |
| Debt to Equity | 0.02x | 0.04x | 0.14x | 0.32x | 0.38x | 0.25x | 0.18x | 0.38x | 0.39x | 0.60x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Haishun New Pharmaceutical Packaging Co Ltd dividends
- Dividend yield
- 3.01%
- Forward dividend
- 0.74 CNY
- Payout ratio
- -
- Ex-dividend date
- Apr 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 87.4M | 0.49 | - |
| 2024 | CNY 88.0M | 0.46 | 118.0% |
| 2023 | CNY 6.25M | 0.03 | 7.3% |
| 2022 | CNY 23.1M | 0.12 | 22.5% |
| 2021 | CNY 7.67M | 0.05 | 7.3% |
| 2020 | CNY 7.67M | 0.05 | 7.5% |
| 2019 | CNY 30.3M | 0.19 | 45.2% |
| 2018 | CNY 34.8M | 0.23 | 52.6% |
| 2017 | CNY 27.0M | 0.18 | 41.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.46:1 on Apr 28, 2026.
Who owns Shanghai Haishun New Pharmaceutical Packaging Co Ltd
- Insiders 56.61%
- Institutions 0.53%
- Public & others 42.87%
- Shares outstanding 278M
- Free float 125M
Shanghai Haishun New Pharmaceutical Packaging Co Ltd company profile
- Company name
- Shanghai Haishun New Pharmaceutical Packaging Co Ltd
- Ticker
- 300501.SHE
- ISIN
- CNE100002607
- Exchange
- Shenzhen Stock Exchange
- Sector
- Consumer Cyclical
- Industry
- Metals & Mining
- Employees
- 1,083
- Fiscal year end
- December
- Address
- No. 3456 Xinzhuan Highway, Shanghai, China, 201619
- Phone
- 86 21 3766 7766
- Website
- hysum.com
About Shanghai Haishun New Pharmaceutical Packaging Co Ltd
HySum Flexibles Global, Inc. engages in the manufacture, sale, and export of pharmaceutical packaging products in China and internationally. The company offers pharmaceutical packaging products, including cold-form, tropical blister foil, PVC/Aclar sheets, PTP lidding, hipack child-resistant packaging, hipack AL/PE strip packs, hipack complex laminated flexible films, lamination foil and pouch, composite films, hipack AL/PE suppository laminates, PVC, PVDC/PVC pharmaceutical packaging, PE series bags, and PP, PE, and COP bottles; and food packaging, comprising three-layer co-extruded PE films, top-blown and bottom-blown multi-layer co-extruded high barrier films, and multi-layer co-extruded sheets. It also provides new energy material packaging, such as aluminum plastic films; precision injection packaging comprising precision injection molded packaging, desiccant combination, precision dosing devices, diagnostic reagent package, and high-barrier vials. The company was formerly known as Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. and changed its name to HySum Flexibles Global, Inc. in January 2024. The company was founded in 2005 and is headquartered in Shanghai, China.
Shanghai Haishun New Pharmaceutical Packaging Co Ltd management
6- Mr. Qin HuangChief Investment Officer, Investment Director, GM & Chairman · born 1968
- Mr. Hailong NiCFO, Financial Director & Non-Independent Director · born 1963
- Mr. Jian FuDeputy GM & Director of Operations · born 1983
- Mr. Ping ChenVP & Deputy GM · born 1974
- Mr. Gaofeng YangBoard Secretary · born 1982
- Yun Bo FanAccounting Supervisor